TP53 and neoplasm: Although measurable clinical activity has been found in a few “first-generation” approaches, such as adenoviral p53 replacement11, highly promising results have recently been obtained utilising replicating viral vectors (oncolytic virotherapy) that help maximise gene transduction in tumour cells.